TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerRachel O. Abelman, Aditya Bardia, Elena Bitman et al.|Clinical Cancer Research|2025Cited by 39
<i>In Vivo</i> Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic VulnerabilitiesElisa ten Hacken, Catherine J. Wu, Tomasz Sewastianik et al.|Blood Cancer Discovery|2022Cited by 27
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.Rachel O. Abelman, Laura M. Spring, Shannon McLaughlin et al.|Journal of Clinical Oncology|2025Cited by 11